CryoPort (CYRX) shares were up nearly 23% in recent Monday trading after UBS Securities upgraded the stock to buy from neutral and maintained its price target of $10.
UBS expects mid-to-long-term sales growth of around 10% and a path to positive free cash flow as CryoPort expands its cell and gene therapy services. While challenges from its MVE subsidiary and broader biopharma market weakness have weighed on revenue, the firm believes these headwinds are stabilizing, creating an attractive entry point.
UBS highlighted CryoPort's significant exposure to cell and gene therapy, noting its leading position in clinical trial logistics and involvement in commercially approved treatments. The firm also expects operating leverage and tapering capital expenditures to support positive free cash flow by 2027.
Trading volume exceeded 643,000 shares, compared with a daily average of about 373,000.
Price: 6.99, Change: +1.30, Percent Change: +22.85
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。